The prevention of anthracycline cardiomyopathy
Open Access
- 1 January 1998
- journal article
- Published by Elsevier BV in Progress in Pediatric Cardiology
- Vol. 8 (3), 97-108
- https://doi.org/10.1016/s1058-9813(98)00006-x
Abstract
No abstract availableThis publication has 66 references indexed in Scilit:
- Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease.Heart, 1993
- Detection of Early Anthracycline Cardiotoxicity by Monitoring the Peak Filling RateAmerican Journal of Clinical Oncology, 1993
- Atrial natriuretic peptide as a marker for doxorubicin-induced cardiotoxic effectsCancer, 1992
- Increasing therapeutic effect and reducing toxicity of doxorubicin by N-acyl dehydroalaninesEuropean Journal of Cancer and Clinical Oncology, 1989
- Amelioration of 4′-epidoxorubicin-induced cardiotoxicity by sodium cromoglycateEuropean Journal of Cancer and Clinical Oncology, 1989
- Doxorubicin cardiotoxicity: Response of left ventricular ejection fraction to exercise and incidence of regional wall motion abnormalitiesThe International Journal of Cardiovascular Imaging, 1988
- Protective Effect of the Bispiperazinedione ICRF-187 against Doxorubicin-Induced Cardiac Toxicity in Women with Advanced Breast CancerThe New England Journal of Medicine, 1988
- Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: Seven-year experience using serial radionuclide angiocardiographyAmerican Journal Of Medicine, 1987
- Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicityAmerican Heart Journal, 1983
- Doxorubicin cardiotoxicity in childrenThe Journal of Pediatrics, 1980